Search
CardioMetabolic_infographic_Update_2021.pdf
Research & Development Video | BI Careers
Prof. Eric Haaksma speaks about his career and the Boehringer Ingelheim mission to transform lives for generations.
Jens Barthelmes
My career challenge at Boehringer Ingelheim by Jens Barthelmes. Read it now!
Accessibility Statement
Accessibility Statement
Learning and development
We help people grow professionally by maximizing our talent and giving them room to evolve within the company.
Emerging Talent
At Boehringer Ingelheim, we know how important it is to lay the right foundations in your career and build on them with care and support.
Victor Emenike
Victor Emenike is a data scientist in operations, specifically in the launch and innovation organization, feels valued and supported in new ideas.
Lothar Halmer
Dr. Lothar Halmer is our Chief Quality Officer, and proud to have built a 25-year career with us.
Transboundary and Emerging Diseases | Boehringer Ingelheim US
Click here to find out more on how Boehringer Ingelheim fights transboundary and emerging diseases through cutting-edge technologies.
Partnering Interests in CardioMetabolic Diseases
Partnering Interests in CardioMetabolic Diseases
PAP Federal Poverty Guidelines Document
Spanish-Enrollment-Form_0.pdf
Anna Mezentseva
Anna Mezentseva talks about being a discovery management trainee in Finance and Controlling.
Medicine & Regulatory Video
Taimi Sahlin, a therapeutic specialist with Boehringer Ingelheim Canada describes her career as challenging and motivating.
EDITABLE-Spanish-Enrollment-form_3.pdf
Partnering-Mental-Health-Disorders_0.pdf
Partnering-Mental-Health-Disorders.pdf
partnering-cardiometabolic_0.pdf
partnering-cardiometabolic.pdf
AH-Partnering-Cardiometabolic-Diseases.pdf
Understand the burden of serious mental illness
More Green | Sustainable Development
Our MORE GREEN pillar encompasses initiatives that consider many different aspects: adopting measures to avoid water and air pollution, & much more.
New affordability initiative with GoodRx for our biosimilar
Boehringer Ingelheim announces patient affordability initiative with GoodRx for biosimilar
Jardiance® (empagliflozin) Tablets Reduce Risk of CV Death | Boehringer Ingelheim US
EMPA-REG OUTCOME® trial: New analyses show that JARDIANCE reduced the risk of CV death in adults with T2D. View ISI, PI and Med Guide.